Cornerstone Advisory’s Matinas BioPharma MTNB Stock Holding History

Cornerstone Advisory’s Portfolio MTNB Stock Details MTNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-1	Closed	–	–	554
2021 Q4	$0	Buy	+1	New	+$53	﹤0.01%	823

Other funds holding MTNB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SIG

Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AWA

Arkadios Wealth Advisors Atlanta, Georgia $6.13B AUM 23.41% 1-Year Est. Return

CCM

Courage Capital Management Nashville, Tennessee $70.6M AUM 13.29% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SCA

STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.36B AUM 23.72% 1-Year Est. Return

Cornerstone Advisory's MTNB Position: Q1 2022 in Review

Cornerstone Advisory sold out of Matinas BioPharma (MTNB) in Q1 2022, closing a stake of 1 share.

Cornerstone Advisory first reported a position in MTNB in Q4 2021 and held it in 1 quarter. The position peaked at $0 in Q4 2021. 56 funds tracked by Wall St. Rank hold MTNB as of Q1 2022.

Cornerstone Advisory reported no remaining Matinas BioPharma position as of Q1 2022 after selling out during the quarter.
Cornerstone Advisory sold 1 Matinas BioPharma share in Q1 2022.
Cornerstone Advisory first reported a position in Matinas BioPharma in Q4 2021 and held it in 1 quarter.
Cornerstone Advisory's Matinas BioPharma position peaked at $0 in Q4 2021.
56 funds tracked by Wall St. Rank held Matinas BioPharma as of Q1 2022.

Based on Cornerstone Advisory's 13F filing for Q1 2022, filed 20 May 2022.